COVID-19 – Wales – Shielding update and Q&A

Filmed on 23/06/2020. We are joined by Dr Steven Knapper, Senior Lecturer and Honorary Consultant Haematologist at the University Hospital Wales and Dr Nilima Parry - Jones consultant haematologist and MDT Chair Aneurin Bevan University Health Board.

23 June 2020

VIDEO RECORDED LIVE on 23/6/2020.

INFORMATION CORRECT AS OF THIS DATE.

Welcome to our 3rd set of webinars on shielding. This time we are talking specifically about the guidance for patients in Wales. We are joined by Dr Steven Knapper, Senior Lecturer and Honorary Consultant Haematologist at the University Hospital Wales and Dr Nilima Parry – Jones consultant haematologist and MDT Chair Aneurin Bevan University Health Board.

We will update and summarise Wales government shielding guidance and support provision; what this now means to patients and their families as shielding evolves.

Any questions, please email advocacy@leukaemiacare.org.uk.

Myelodysplastic syndromes (MDS)

Myelodysplastic syndromes (MDS) are diseases of the bone marrow. MDS is characterised by abnormal, immature blood cells that do not work properly. MDS is a type of cancer, but it is sometimes also called ‘bone marrow failure’. Here, we cover what MDS is, how it’s diagnosed, and what treatment you might have.